BIO
Andreas Lysandropoulos, M.D., Ph.D.
Franchise Head, Neurosciences, Ophthalmology, and Rare Diseases
As head of the Neuroscience Global Therapeutic Area, Andreas is responsible for working with clients to create effective development strategies. With the plan in place, he and his team lead all aspects of execution, with the aim of ensuring that assets are approved quickly and efficiently.
Work Experience
Andreas has more than 15 years of experience as a clinical neurologist with expertise in neuroimmunology and multiple sclerosis (MS). Before joining Parexel, he served as head of Global Medical Affairs in Neuroscience with Ipsen, and as director of Medical Affairs Europe, MS with Sanofi Genzyme. In the healthcare setting, Andreas was head of the Neuroimmunology Unit at University Hospital in Brussels, Belgium, and has also served as principal investigator in global Phase II-IV clinical studies. He is co-founder of ParadigMS, an organization dedicated to improving MS patient care.
Education
Andreas holds a Ph.D. in Medicine from the University of Brussels. He is a board-certified neurologist in Switzerland and is board-certified in Medical Affairs, ACMA in Belgium.
More By This Expert
CTB Blog
The essential role of translation in early phase neurology research
Webinar
Alzheimer’s Disease vs Multiple Sclerosis Drug Development: Similarities, Differences & New Perspectives
Article
We can accelerate neuroscience research with courage and urgency
Q&A
To increase inclusion in neuroscience, we need a broader definition
Article
Breakthrough designations granted by CDER's Office of Neuroscience in 2024
Op-Ed
Breaking Boundaries: Cross-Therapeutic Innovation to Revolutionize Neuroscience Trials
Blog
As more neuroscience drugs are approved, the value proposition takes center stage
Blog
Improving and accelerating clinical research in dementia by integrating the patient’s voice throughout the development journey
Podcast
Navigating market access in neuroscience: Challenges and strategies
Op-Ed
Can innovative trial designs work in neuroscience?
Podcast
Is There Room for New COAs in Neuroscience?
Video
The future of Parkinson’s Disease treatment: From digital measures to disease modification
Video
Leveraging Patient Insight in MS Trials
Article
How real-world evidence can support a compelling value story for neuroscience assets
Blog
Newly released FDA data and approvals signal a more welcoming regulatory environment for neuroscience clinical trials
CTB Blog
The essential role of translation in early phase neurology research
Webinar
Alzheimer’s Disease vs Multiple Sclerosis Drug Development: Similarities, Differences & New Perspectives
Article
We can accelerate neuroscience research with courage and urgency
Q&A
To increase inclusion in neuroscience, we need a broader definition
Article
Breakthrough designations granted by CDER's Office of Neuroscience in 2024
Op-Ed
Breaking Boundaries: Cross-Therapeutic Innovation to Revolutionize Neuroscience Trials
Blog
As more neuroscience drugs are approved, the value proposition takes center stage
Blog
Improving and accelerating clinical research in dementia by integrating the patient’s voice throughout the development journey
Podcast
Navigating market access in neuroscience: Challenges and strategies
Op-Ed
Can innovative trial designs work in neuroscience?
Podcast
Is There Room for New COAs in Neuroscience?
Video
The future of Parkinson’s Disease treatment: From digital measures to disease modification
Video
Leveraging Patient Insight in MS Trials
Article
How real-world evidence can support a compelling value story for neuroscience assets
Blog
Newly released FDA data and approvals signal a more welcoming regulatory environment for neuroscience clinical trials
Discover the
heart of Parexel:
our people
heart of Parexel:
our people
Learn More